|
|
|
Volumn 25, Issue 5 SUPPL. 12, 1998, Pages 7-11
|
|
Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: A preliminary report of the randomized phase III trial
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
DOXORUBICIN;
PACLITAXEL;
ARTICLE;
BREAST CANCER;
CLINICAL TRIAL;
CONTINUOUS INFUSION;
CONTROLLED STUDY;
DIARRHEA;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
NAUSEA;
NEUROTOXICITY;
NEUTROPENIA;
PATIENT SELECTION;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
SKIN TOXICITY;
VOMITING;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
BREAST NEOPLASMS;
DOXORUBICIN;
HUMANS;
NEOPLASM METASTASIS;
PACLITAXEL;
TAXOIDS;
TREATMENT FAILURE;
|
|
EID: 0031743847
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (28)
|
|
References (25)
|
